INDP Indaptus Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1857044 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.0%
TTM EPS YoY89.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-180.7%
ROA-70.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets66.9%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $271,204 | $363,127 | $491,134 | $2.85M | $1.52M | $2.17M | $2.81M | $2.48M |
| SG&A expense | $864,663 | $1.45M | $1.67M | $5.31M | $1.13M | $2.29M | $1.76M | $1.69M |
| Operating income | -$1.14M | -$1.81M | -$2.16M | -$8.16M | -$2.65M | -$4.46M | -$4.57M | -$4.17M |
| Net income | -$1.05M | -$1.79M | -$2.54M | -$8.11M | -$2.98M | -$5.23M | -$4.53M | -$4.13M |
| EBITDA | — | — | — | — | — | — | — | -$4.17M |
| EPS (basic) | -0.01 | -0.02 | -0.23 | — | -2.98 | -9.09 | -9.11 | — |
| EPS (diluted) | -0.01 | -0.02 | -0.23 | — | -2.98 | -9.09 | -9.11 | — |
| Weighted avg. shares (diluted) | 133.24M | 116.13M | 10.96M | — | 997,038 | 574,923 | 497,794 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.60M | $7.55M | $1.50M | $8.51M | $5.83M | $6.16M | $3.89M | $5.79M |
| Short-term investments | $4.00M | $4.00M | — | — | — | — | — | — |
| Current assets | — | — | $2.18M | $9.31M | $6.44M | $6.41M | $4.96M | $6.62M |
| Total assets | $31.21M | $11.99M | — | $9.31M | $6.84M | $6.84M | $5.41M | $7.34M |
| Current liabilities | — | — | $932,999 | $6.16M | $2.23M | $8.51M | $2.61M | $3.39M |
| Total liabilities | $20.88M | $615,426 | $932,999 | $6.16M | $2.23M | $8.51M | $2.61M | $3.39M |
| Shareholders' equity | $10.33M | $11.37M | $1.25M | $3.15M | $4.61M | -$1.67M | $2.80M | $3.94M |
| Shares outstanding | 133.24M | 133.24M | 113.24M | 2.17M | 1.64M | 604,963 | 16.03M | 428,799 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.44M | -$1.93M | -$7.01M | -$3.19M | -$2.57M | -$4.02M | -$5.05M | -$3.40M |
| Investing cash flow | $0 | — | — | — | — | — | — | — |
| Financing cash flow | $20.49M | — | — | $5.87M | $2.24M | $6.28M | $3.15M | $1.80M |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $8,372 | -$64,283 | $227,180 | $785,814 | $150,614 | $180,763 | $240,891 | $304,122 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.